p.71 抽出テキスト

steroid therapy in cardiac sarcoidosis. Heart 2014; 100: 1165- 1172. PMID: 24829369 82. Bekki M, Tahara N, Tahara A, et al. Localization of myocardial FDG uptake for prognostic risk stratification in corticosteroidnaïve cardiac sarcoidosis. J Nucl Cardiol 2022; 29: 2132- 2144. PMID: 34228338 83. Gowani Z, Habibi M, Okada DR, et al. Utility of cardiac magnetic resonance imaging versus cardiac positron emission tomography for risk stratification for ventricular arrhythmias in patients with cardiac sarcoidosis. Am J Cardiol 2020; 134: 123- 129. PMID: 32950203 84. Kazmirczak F, Chen KA, Adabag S, et al. Assessment of the 2017 AHA/ACC/HRS guideline recommendations for implantable cardioverter-defibrillator implantation in cardiac sarcoidosis. Circ Arrhythm Electrophysiol 2019; 12: e007488. PMID: 31431050 85. Takenaka S, Kobayashi Y, Nagai T, et al. Applicability of the AHA/ ACC/HRS guideline for implantable cardioverter defibrillator implantation in Japanese patients with cardiac sarcoidosis. JACC Clin Electrophysiol 2021; 7: 1410-1418. PMID: 34217654 86. Ogura S, Nakamura K, Morita H, et al. Fragmented QRS as a predictor of cardiac events in patients with cardiac sarcoidosis. J Cardiol 2022; 79: 446-452. PMID: 34799215 87. Hagiwara H, Watanabe M, Kadosaka T, et al. Fragmented QRS on 12-lead electrocardiogram predicts long-term prognosis in patients with cardiac sarcoidosis. Heart Vessels 2023; 38: 803-816. PMID: 36635468 88. Kobayashi Y, Nagai T, Takenaka S, et al. Long-term prognostic significance of ventricular repolarization dispersion in patients with cardiac sarcoidosis. Am J Cardiol 2021; 152: 125- 131. PMID: 34127248 89. Nagano N, Nagai T, Sugano Y, et al. Association between basal thinning of interventricular septum and adverse long-term clinical outcomes in patients with cardiac sarcoidosis. Circ J 2015; 79: 1601-1608. PMID: 25947001 90. Nordenswan HK, Pöyhönen P, Lehtonen J, et al. Incidence of sudden cardiac death and life-threatening arrhythmias in clinically manifest cardiac sarcoidosis with and without current indications for an implantable cardioverter defibrillator. Circulation 2022; 146: 964-975. PMID: 36000392 91. Roberts PR, ElRefai M, Foley P, et al. UK expert consensus statement for the optimal use and clinical utility of leadless pacing systems on behalf of the British Heart Rhythm Society. Arrhythm Electrophysiol Rev 2022; 11: e19. PMID: 36304202 92. Strik M, Clementy N, Mondoly P, et al. Implantation of a leadless pacemaker in young adults. J Cardiovasc Electrophysiol 2023; 34: 412-417. PMID: 36583963 93. Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 2021; 42: 3427-3520. PMID: 34455430 94. Crossley GH, Piccini JP, Longacre C, et al. Leadless versus transvenous single-chamber ventricular pacemakers: 3 year follow-up of the Micra CED study. J Cardiovasc Electrophysiol 2023; 34: 1015-1023. PMID: 36807378 95. Knops RE, Reddy VY, Ip JE, et al. Aveir DR i2i Study Investigators. A dual-chamber leadless pacemaker. N Engl J Med 2023; 388: 2360-2370. PMID: 37212442 96. Reddy VY, Exner DV, Doshi R, et al. LEADLESS II Investigators. Primary results on safety and efficacy from the LEADLESS II-Phase 2 worldwide clinical trial. JACC Clin Electrophysiol 2022; 8: 115-117. PMID: 34863657 97. Neuzil P, Petru J, Chovanec M, et al. PO- 693- 05 removal of a chronically-implanted leadless ventricular pacemaker after 9-years using a highly torque retrieval catheter a case report. Heart Rhythm 2022: 19 Suppl: S407-S408. 98. Steinwender C, Khelae SK, Garweg C, et al. Atrioventricular synchronous pacing using a leadless ventricular pacemaker: results from the MARVEL 2 study. JACC Clin Electrophysiol 2020; 6: 94-106. PMID: 31709982 99. Chinitz LA, El-Chami MF, Sagi V, et al. Ambulatory atrioventricular synchronous pacing over time using a leadless ventricular pacemaker: primary results from the AccelAV study. Heart Rhythm 2023; 20: 46-54. PMID: 36075532 100. Neugebauer F, Noti F, van Gool S, et al. Leadless atrioventricular synchronous pacing in an outpatient setting: early lessons learned on factors affecting atrioventricular synchrony. Heart Rhythm 2022; 19: 748-756. PMID: 34971817 101. Reynolds D, Duray GZ, Omar R, et al. Micra Transcatheter Pacing Study Group. A leadless intracardiac transcatheter pacing system. N Engl J Med 2016; 374: 533-541. PMID: 26551877 102. Garg A, Koneru JN, Fagan DH, et al. Morbidity and mortality in patients precluded for transvenous pacemaker implantation: experience with a leadless pacemaker. Heart Rhythm 2020; 17: 2056-2063. PMID: 32763431 103. Piccini JP, Cunnane R, Steffel J, et al. Development and validation of a risk score for predicting pericardial effusion in patients undergoing leadless pacemaker implantation: experience with the Micra transcatheter pacemaker. Europace 2022; 24: 1119-1126. PMID: 35025987 104. Ando K, Inoue K, Harada T, et al. Safety and performance of the Micra VR leadless pacemaker in a Japanese cohort ― comparison with global studies. Circ J 2 0 2 3 ; 8 7 : 1 8 0 9 - 1 8 1 6 . PMID: 37532552 105. Beccarino NJ, Choi EY, Liu B, et al. Concomitant leadless pacing in pacemaker-dependent patients undergoing transvenous lead extraction for active infection: mid-term follow-up. Heart Rhythm 2023; 20: 853-860. PMID: 36764351 106. Breeman KTN, Beurskens NEG, Driessen AHG, et al. Timing and mid-term outcomes of using leadless pacemakers as replacement for infected cardiac implantable electronic devices. J Interv Card Electrophysiol 2023; 66: 1477-1485. PMID: 36534325 107. Bicong L, Allen JC, Arps K, et al. Leadless pacemaker implantation after lead extraction for cardiac implanted electronic device infection. J Cardiovasc Electrophysiol 2022; 33: 464-470. PMID: 35029307 108. Mitacchione G, Schiavone M, Gasperetti A, et al. Outcomes of leadless pacemaker implantation following transvenous lead extraction in high-volume referral centers: real-world data from a large international registry. Heart Rhythm 2023; 20: 395- 404. PMID: 36496135 109. Occhetta E, Bortnik M, Audoglio R, et al. INVASY Study Investigators. Closed loop stimulation in prevention of vasovagal syncope. Inotropy Controlled Pacing in Vasovagal Syncope (INVASY): a multicentre randomized, single blind, controlled study. Europace 2004; 6: 538-547. PMID: 15519257 110. Russo V, Rago A, Papa AA, et al. The effect of dual-chamber closed-loop stimulation on syncope recurrence in healthy patients with tilt-induced vasovagal cardioinhibitory syncope: a prospective, randomised, single-blind, crossover study. Heart 2013; 99: 1609- 1613. PMID: 23723446 111. Baron-Esquivias G, Morillo CA, Moya-Mitjans A, et al. Dualchamber pacing with closed loop stimulation in recurrent reflex vasovagal syncope: the SPAIN study. J Am Coll Cardiol 2017; 70: 1720-1728. PMID: 28958328 112. Brignole M, Russo V, Arabia F, et al. BioSync CLS trial Investigators. Cardiac pacing in severe recurrent reflex syncope and tilt-induced asystole. Eur Heart J 2021; 42: 508-516. PMID: 33279955 113. Barón-Esquivias G, Moya-Mitjans A, Martinez-Alday J, et al. Impact of dual-chamber pacing with closed loop stimulation on quality of life in patients with recurrent reflex vasovagal syncope: results of the SPAIN study. Europace 2020; 22: 314-319. PMID: 31713631 114. Russo V, Rago A, De Rosa M, et al. Does cardiac pacing reduce syncopal recurrences in cardioinhibitory vasovagal syncope patients selected with head-up tilt test? Analysis of a 5-year follow-up database. Int J Cardiol 2018; 270: 149- 153. PMID: 29980368 115. Palmisano P, Dell’Era G, Russo V, et al. Effects of closed-loop stimulation vs. DDD pacing on haemodynamic variations and occurrence of syncope induced by head-up tilt test in older patients with refractory cardioinhibitory vasovagal syncope: the Tilt test-Induced REsponse in Closed-loop Stimulation multicentre, prospective, single blind, randomized study. Europace 2018; 20: 859-866. PMID: 28407148 116. Fananapazir L, Epstein ND, Curiel RV, et al. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 1994; 90: 2731-2742. PMID: 7994815 117. Knops RE, Pepplinkhuizen S, Delnoy PPHM, et al. Device-related complications in subcutaneous versus transvenous ICD: a secondary analysis of the PRAETORIAN trial. Eur Heart J 2022; 43: 4872-4883. PMID: 36030464 118. Breeman KTN, Swackhamer B, Brisben AJ, et al. Long-term performance of a novel communicating antitachycardia pacingenabled leadless pacemaker and subcutaneous implantable cardioverter-defibrillator system: a comprehensive preclinical study. Heart Rhythm 2022; 19: 837-846. PMID: 35066181 119. Quast ABE, Tjong FVY, Koop BE, et al. Device orientation of a leadless pacemaker and subcutaneous implantable cardioverterdefibrillator in canine and human subjects and the effect on intrabody communication. Europace 2018; 20: 1866-1871. PMID: 29462311